findmyKOL

Michael Mugavero

Basic profile

University of Alabama at Birmingham

ORCIDNPI
RegionBirmingham, AL · SoutheastSpecialtyInfectious DiseaseFocusInfectious Disease
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2020Online presenceNot yet checkedPaymentsNone reportedNIH funding2008–2026Why? →

Michael Mugavero is an Infectious Disease physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 480 publications with 19,491 citations (h-index 74); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Infectious Disease profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
480publications

Distinct works indexed by OpenAlex, matched via ORCID.

19,491citations

Total citations across indexed works.

74h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials
8NIH grants · 2008–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1717 6th Ave S
Birmingham, AL 352331801

Telephone

800-822-8816

Registry record last updated 1 Feb 2024.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2022)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    27.9%
    Calcium channel blocker17.3%
    Amlodipine Besylate100%
    Part D<11 patients
    Statin10.6%
    Atorvastatin Calcium100%
    Part D<11 patients
  • Nervous system

    26%
    Gabapentinoids15.4%
    Gabapentin100%
    Part D<11 patients
    SSRI10.6%
    Trazodone Hcl100%
    Part D<11 patients
  • Anti-infectives

    25%
    Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor12.5%
    Dovato100%
    Part D<11 patients
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12.5%
    Valacyclovir100%
    Part D<11 patients
Where care is delivered (Part B), 20210% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

8 NIH research awards on record, funded 20082026 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”